Annual FCF
-$41.69 M
+$1.13 B+96.45%
01 December 2023
Summary:
Sinovac Biotech annual free cash flow is currently -$41.69 million, with the most recent change of +$1.13 billion (+96.45%) on 01 December 2023. During the last 3 years, it has fallen by -$393.35 million (-111.86%). SVA annual FCF is now -100.28% below its all-time high of $14.63 billion, reached on 31 December 2021.SVA Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
N/A
01 June 2024
Summary:
Sinovac Biotech quarterly free cash flow is not available.SVA Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
N/A
01 June 2024
Summary:
Sinovac Biotech TTM free cash flow is not available.SVA TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SVA Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -111.9% | - | - |
| 5 y5 years | -1889.3% | - | - |
SVA Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -100.3% | +96.5% | ||||
| 5 y | 5 years | -100.3% | +96.5% | ||||
| alltime | all time | -100.3% | +96.5% |
Sinovac Biotech Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$41.69 M(-96.4%) | - | - |
| Dec 2022 | -$1.17 B(-108.0%) | - | - |
| Dec 2021 | $14.63 B(+4061.0%) | - | - |
| Dec 2020 | $351.66 M(+1136.2%) | $423.23 M(-2301.2%) | $351.66 M(-847.7%) |
| Sept 2020 | - | -$19.23 M(-38.2%) | -$47.03 M(+153.3%) |
| June 2020 | - | -$31.09 M(+46.3%) | -$18.57 M(-212.9%) |
| Mar 2020 | - | -$21.25 M(-186.6%) | $16.45 M(-42.2%) |
| Dec 2019 | $28.45 M(+1120.9%) | $24.54 M(+165.6%) | $28.45 M(+165.9%) |
| Sept 2019 | - | $9.24 M(+134.9%) | $10.70 M(-16.2%) |
| June 2019 | - | $3.93 M(-142.5%) | $12.76 M(-3110.4%) |
| Mar 2019 | - | -$9.26 M(-236.5%) | -$424.00 K(-118.2%) |
| Dec 2018 | $2.33 M(-95.1%) | $6.79 M(-40.0%) | $2.33 M(-152.3%) |
| Sept 2018 | - | $11.31 M(-222.1%) | -$4.46 M(-71.7%) |
| June 2018 | - | -$9.26 M(+42.3%) | -$15.76 M(+142.3%) |
| Mar 2018 | - | -$6.51 M(+126.8%) | -$6.51 M(-75.5%) |
| Dec 2017 | $47.84 M(-280.2%) | - | - |
| Dec 2016 | -$26.56 M(+2340.8%) | -$2.87 M(-18.4%) | -$26.56 M(+146.3%) |
| Sept 2016 | - | -$3.51 M(-50.4%) | -$10.78 M(+1.3%) |
| June 2016 | - | -$7.09 M(-45.9%) | -$10.65 M(+153.5%) |
| Mar 2016 | - | -$13.09 M(-201.4%) | -$4.20 M(+286.0%) |
| Dec 2015 | -$1.09 M(-94.8%) | $12.90 M(-482.1%) | -$1.09 M(-90.6%) |
| Sept 2015 | - | -$3.38 M(+427.7%) | -$11.58 M(-20.5%) |
| June 2015 | - | -$640.00 K(-93.6%) | -$14.56 M(-36.7%) |
| Mar 2015 | - | -$9.98 M(-513.1%) | -$23.01 M(+9.4%) |
| Dec 2014 | -$21.04 M(-4849.4%) | $2.42 M(-138.0%) | -$21.04 M(+330.0%) |
| Sept 2014 | - | -$6.36 M(-30.1%) | -$4.89 M(-4.4%) |
| June 2014 | - | -$9.09 M(+13.6%) | -$5.12 M(-3127.8%) |
| Mar 2014 | - | -$8.00 M(-143.1%) | $169.00 K(-61.9%) |
| Dec 2013 | $443.00 K | $18.56 M(-382.0%) | $443.00 K(-102.9%) |
| Sept 2013 | - | -$6.58 M(+72.9%) | -$15.15 M(-20.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | - | -$3.81 M(-50.7%) | -$19.15 M(-24.3%) |
| Mar 2013 | - | -$7.73 M(-360.3%) | -$25.31 M(-21.9%) |
| Dec 2012 | -$32.41 M(+2030.8%) | $2.97 M(-128.1%) | -$32.41 M(+26.5%) |
| Sept 2012 | - | -$10.58 M(+6.2%) | -$25.61 M(+56.7%) |
| June 2012 | - | -$9.97 M(-32.8%) | -$16.34 M(+117.8%) |
| Mar 2012 | - | -$14.83 M(-251.9%) | -$7.50 M(+393.5%) |
| Dec 2011 | -$1.52 M(-96.2%) | $9.77 M(-844.7%) | -$1.52 M(-85.9%) |
| Sept 2011 | - | -$1.31 M(+16.0%) | -$10.76 M(-51.7%) |
| June 2011 | - | -$1.13 M(-87.2%) | -$22.26 M(-24.9%) |
| Mar 2011 | - | -$8.84 M(-1775.1%) | -$29.64 M(-25.3%) |
| Dec 2010 | -$39.66 M(-189.9%) | $528.00 K(-104.1%) | -$39.66 M(+2786.3%) |
| Sept 2010 | - | -$12.81 M(+50.4%) | -$1.37 M(-108.0%) |
| June 2010 | - | -$8.52 M(-54.8%) | $17.17 M(-48.1%) |
| Mar 2010 | - | -$18.86 M(-148.6%) | $33.08 M(-25.0%) |
| Dec 2009 | $44.09 M(+575.4%) | $38.81 M(+576.3%) | $44.09 M(+196.2%) |
| Sept 2009 | - | $5.74 M(-22.3%) | $14.88 M(+30.5%) |
| June 2009 | - | $7.38 M(-194.2%) | $11.41 M(+942.2%) |
| Mar 2009 | - | -$7.84 M(-181.7%) | $1.09 M(-83.2%) |
| Dec 2008 | $6.53 M(+252.9%) | $9.60 M(+325.1%) | $6.53 M(-312.2%) |
| Sept 2008 | - | $2.26 M(-177.2%) | -$3.08 M(-42.3%) |
| June 2008 | - | -$2.93 M(+21.4%) | -$5.34 M(+121.4%) |
| Mar 2008 | - | -$2.41 M | -$2.41 M |
| Dec 2007 | $1.85 M(-166.6%) | - | - |
| Dec 2006 | -$2.78 M(-30.9%) | - | - |
| Dec 2005 | -$4.01 M(+25.9%) | - | - |
| Dec 2004 | -$3.19 M(+30.0%) | - | - |
| Dec 2003 | -$2.45 M(+4070.7%) | - | - |
| Apr 2002 | -$58.80 K(-88.2%) | - | - |
| Apr 2001 | -$498.50 K(+25.5%) | - | - |
| Apr 2000 | -$397.20 K | - | - |
FAQ
- What is Sinovac Biotech annual free cash flow?
- What is the all time high annual FCF for Sinovac Biotech?
- What is the all time high quarterly FCF for Sinovac Biotech?
- What is the all time high TTM FCF for Sinovac Biotech?
What is Sinovac Biotech annual free cash flow?
The current annual FCF of SVA is -$41.69 M
What is the all time high annual FCF for Sinovac Biotech?
Sinovac Biotech all-time high annual free cash flow is $14.63 B
What is the all time high quarterly FCF for Sinovac Biotech?
Sinovac Biotech all-time high quarterly free cash flow is $423.23 M
What is the all time high TTM FCF for Sinovac Biotech?
Sinovac Biotech all-time high TTM free cash flow is $351.66 M